Andrew Coveler, MD, discusses the potential clinical implications of positive data with NUC-3373 in metastatic colorectal cancer.
Andrew Coveler, MD
Advertisement
Articles by Andrew Coveler, MD
Andrew Coveler, MD, discusses the toxicity profile of NUC-3373 in metastatic colorectal cancer.
Andrew Coveler, MD, discusses the rationale to evaluate NUC-3373 in metastatic colorectal cancer.
Andrew Coveler, MD, discusses the investigational CD40-directed monoclonal antibody SEA-CD40 in combination with gemcitabine, nab-paclitaxel, and pembrolizumab in patients with metastatic pancreatic ductal adenocarcinoma.
Advertisement
Latest Updated Articles
Advertisement
Advertisement
Trending on OncLive
1
Lurbinectedin-Based Triplet Shows Clinical Benefit in Advanced Soft Tissue Sarcoma
2
Ultra-Sensitive ctDNA and CSF Liquid Biopsy May Refine Monitoring and Adaptive Trial Designs in Metastatic Breast Cancer
3
Anti–Gremlin-1 Therapy Plus Chemo Makes Waves in GI Malignancies
4
FDA Grants Fast Track Designation to IBI3003 in Relapsed/Refractory Multiple Myeloma
5